Clinical Trial Update: Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia [Phase 2]

View source ↗

Summary

Phase 2 trial of Orlistat with SLx-4090 for Type 1 Hyperlipoproteinemia was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Hyperlipoproteinemia

Drugs mentioned

• Orlistat (orlistat)
• SLx-4090 (SLx-4090)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Type 1 Hyperlipoproteinemia | Phase 2 | Status: TERMINATED | Results posted: 2021-08-19